Livforsakringsbolaget Skandia Omsesidigt Increases Stock Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Livforsakringsbolaget Skandia Omsesidigt increased its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 6.2% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,543 shares of the medical equipment provider's stock after purchasing an additional 500 shares during the period. Livforsakringsbolaget Skandia Omsesidigt's holdings in Intuitive Surgical were worth $4,230,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Ameliora Wealth Management Ltd. boosted its position in shares of Intuitive Surgical by 872.2% during the first quarter. Ameliora Wealth Management Ltd. now owns 350 shares of the medical equipment provider's stock worth $173,000 after acquiring an additional 314 shares during the last quarter. Simplicity Wealth LLC lifted its stake in Intuitive Surgical by 108.9% in the 1st quarter. Simplicity Wealth LLC now owns 1,389 shares of the medical equipment provider's stock worth $688,000 after purchasing an additional 724 shares in the last quarter. GAMMA Investing LLC boosted its holdings in shares of Intuitive Surgical by 9.3% during the 1st quarter. GAMMA Investing LLC now owns 6,115 shares of the medical equipment provider's stock valued at $3,029,000 after purchasing an additional 518 shares during the last quarter. Wealthcare Advisory Partners LLC grew its position in shares of Intuitive Surgical by 26.4% during the first quarter. Wealthcare Advisory Partners LLC now owns 5,060 shares of the medical equipment provider's stock valued at $2,506,000 after purchasing an additional 1,056 shares in the last quarter. Finally, Tounjian Advisory Partners LLC bought a new stake in shares of Intuitive Surgical in the first quarter worth about $5,152,000. 83.64% of the stock is currently owned by institutional investors.

Intuitive Surgical Price Performance

Shares of NASDAQ:ISRG traded down $5.35 during trading hours on Wednesday, hitting $524.26. The company's stock had a trading volume of 475,814 shares, compared to its average volume of 1,656,614. The company has a market capitalization of $187.90 billion, a price-to-earnings ratio of 81.74, a P/E/G ratio of 5.85 and a beta of 1.67. The firm's fifty day moving average price is $523.08 and its 200 day moving average price is $538.95. Intuitive Surgical, Inc. has a 52 week low of $413.82 and a 52 week high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last issued its quarterly earnings data on Tuesday, April 22nd. The medical equipment provider reported $1.81 earnings per share for the quarter, beating analysts' consensus estimates of $1.71 by $0.10. The company had revenue of $2.25 billion for the quarter, compared to the consensus estimate of $2.19 billion. Intuitive Surgical had a return on equity of 14.55% and a net margin of 27.81%. During the same quarter last year, the company earned $1.50 earnings per share. On average, equities research analysts predict that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have weighed in on ISRG shares. Evercore ISI cut their price target on Intuitive Surgical from $510.00 to $470.00 and set an "in-line" rating for the company in a report on Wednesday, April 23rd. Piper Sandler reduced their price target on shares of Intuitive Surgical from $670.00 to $575.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 23rd. Citigroup reiterated a "buy" rating and set a $650.00 price objective (up previously from $590.00) on shares of Intuitive Surgical in a research report on Thursday, May 22nd. Truist Financial reduced their target price on shares of Intuitive Surgical from $605.00 to $590.00 and set a "buy" rating on the stock in a report on Wednesday, April 23rd. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of Intuitive Surgical from a "hold" rating to a "sell" rating and lowered their price target for the company from $515.00 to $440.00 in a report on Monday. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $588.95.

Insider Transactions at Intuitive Surgical

In other Intuitive Surgical news, EVP Robert Desantis sold 11,545 shares of the firm's stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $499.22, for a total transaction of $5,763,494.90. Following the completion of the transaction, the executive vice president now directly owns 5,224 shares of the company's stock, valued at approximately $2,607,925.28. This trade represents a 68.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Jami K. Nachtsheim sold 2,400 shares of the stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $520.00, for a total value of $1,248,000.00. Following the sale, the director now directly owns 6,371 shares in the company, valued at $3,312,920. This represents a 27.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 16,543 shares of company stock valued at $8,375,072 in the last 90 days. Insiders own 0.70% of the company's stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.